Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Pharmaust Limited ( (AU:NUZ) ) has shared an update.
Neurizon Therapeutics Limited has announced a change in its registered office and principal place of business to a new address in Melbourne, Australia. This move is part of the company’s ongoing efforts to enhance its operations as it continues to advance its clinical-stage treatments for neurodegenerative diseases. The change is effective immediately, and all other contact details remain unchanged. This development reflects Neurizon’s strategic focus on strengthening its position in the biotech industry and its commitment to addressing complex neural disorders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Their lead drug candidate, NUZ-001, is aimed at treating ALS, the most common form of motor neurone disease. The company is committed to accelerating access to effective ALS treatments and exploring broader applications for NUZ-001 through international collaborations and rigorous clinical programs.
YTD Price Performance: -20.59%
Average Trading Volume: 343,731
Technical Sentiment Signal: Sell
Current Market Cap: A$66.46M
See more data about NUZ stock on TipRanks’ Stock Analysis page.